Wall Street brokerages forecast that Revance Therapeutics Inc (NASDAQ:RVNC) will report sales of $1.95 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Revance Therapeutics’ earnings. The highest sales estimate is $2.60 million and the lowest is $500,000.00. Revance Therapeutics posted sales of $40,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 4,775%. The business is expected to issue its next quarterly earnings report after the market closes on Wednesday, February 27th.
According to Zacks, analysts expect that Revance Therapeutics will report full-year sales of $5.18 million for the current year, with estimates ranging from $3.70 million to $5.84 million. For the next financial year, analysts expect that the firm will post sales of $10.76 million, with estimates ranging from $2.00 million to $22.00 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that follow Revance Therapeutics.
Several equities analysts recently commented on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and set a $50.00 target price on shares of Revance Therapeutics in a report on Thursday, November 1st. Zacks Investment Research upgraded Revance Therapeutics from a “hold” rating to a “strong-buy” rating and set a $20.00 price target on the stock in a report on Tuesday, January 22nd. BidaskClub downgraded Revance Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, November 16th. Mizuho reaffirmed a “buy” rating on shares of Revance Therapeutics in a research note on Friday, January 18th. Finally, ValuEngine upgraded Revance Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, December 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Revance Therapeutics has a consensus rating of “Buy” and a consensus target price of $44.88.
NASDAQ RVNC opened at $17.78 on Thursday. Revance Therapeutics has a 1-year low of $16.56 and a 1-year high of $34.55. The company has a market capitalization of $660.61 million, a PE ratio of -4.43 and a beta of 0.86.
A number of institutional investors and hedge funds have recently modified their holdings of RVNC. Geode Capital Management LLC increased its holdings in shares of Revance Therapeutics by 14.3% during the 4th quarter. Geode Capital Management LLC now owns 385,818 shares of the biopharmaceutical company’s stock valued at $7,766,000 after acquiring an additional 48,325 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Revance Therapeutics by 197.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 225,708 shares of the biopharmaceutical company’s stock worth $4,543,000 after purchasing an additional 149,952 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Revance Therapeutics in the fourth quarter valued at $210,000. Citigroup Inc. lifted its position in Revance Therapeutics by 134.5% in the 4th quarter. Citigroup Inc. now owns 20,108 shares of the biopharmaceutical company’s stock valued at $405,000 after acquiring an additional 11,532 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Revance Therapeutics by 3.1% during the 4th quarter. Bank of New York Mellon Corp now owns 2,542,242 shares of the biopharmaceutical company’s stock worth $51,175,000 after purchasing an additional 77,625 shares during the last quarter. Hedge funds and other institutional investors own 92.65% of the company’s stock.
About Revance Therapeutics
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.
Recommended Story: Blue-Chip Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.